Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$13.89 - $15.04 $213,267 - $230,924
15,354 New
15,354 $213,000
Q3 2023

Nov 14, 2023

SELL
$15.03 - $16.32 $185,440 - $201,356
-12,338 Reduced 37.0%
21,007 $324,000
Q2 2023

Aug 14, 2023

BUY
$15.57 - $17.11 $519,181 - $570,532
33,345 New
33,345 $523,000
Q3 2022

Nov 14, 2022

BUY
$12.8 - $28.65 $533,580 - $1.19 Million
41,686 Added 280.98%
56,522 $733,000
Q2 2022

Aug 15, 2022

BUY
$13.12 - $15.03 $194,648 - $222,985
14,836 New
14,836 $208,000
Q3 2021

Nov 15, 2021

SELL
$16.3 - $17.26 $956,435 - $1.01 Million
-58,677 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$16.55 - $18.64 $971,104 - $1.09 Million
58,677 New
58,677 $988,000
Q2 2020

Aug 14, 2020

SELL
$14.59 - $19.5 $231,163 - $308,958
-15,844 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$13.02 - $20.31 $206,288 - $321,791
15,844 New
15,844 $241,000
Q2 2019

Aug 14, 2019

SELL
$16.58 - $20.49 $5.72 Million - $7.06 Million
-344,714 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$16.7 - $21.52 $5.76 Million - $7.42 Million
344,714 New
344,714 $7.02 Million

Others Institutions Holding TAK

About TAKEDA PHARMACEUTICAL CO LTD


  • Ticker TAK
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 3,109,050,112
  • Market Cap $40.9B
  • Description
  • Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...
More about TAK
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.